Qiagen N.V. reported $2.09B of revenue over the trailing twelve months, +5.7% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.09B (to FY2025). Net income: $425M, trailing twelve months to FY2025. Free cash flow: $453M, trailing twelve months to FY2025. Operating margin: 22%, trailing twelve months to FY2025.

QGENQiagen N.V.

Healthcare

$45.40-1.2% 1Y

$45.40

$32.6352 weeks$55.66

QGEN as reported

Qiagen N.V. reported $2.09B of revenue over the trailing twelve months, +5.7% on the year before. 11 reported series are charted on this page, each one as filed.

$2.09B

Revenue, trailing twelve months · to FY2025 · +5.7% against the twelve months before

Net income: $425M
Net income · +408% year on year · trailing twelve months to FY2025
Free cash flow: $453M
Free cash flow · −10% year on year · trailing twelve months to FY2025
Operating margin: 22%
Operating margin · trailing twelve months to FY2025

Details›

Every series Ryufin has for QGEN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.09B	+5.7%	FY2025
Net income	$425M	+408%	FY2025
EPS	$1.94	+424%	FY2025
Gross margin	62%	n/a	FY2025
Operating margin	22%	n/a	FY2025
Net margin	20%	n/a	FY2025
ROE	11%	n/a	FY2025
ROA	6.8%	n/a	FY2025
ROIC	8.5%	n/a	FY2025
Free cash flow	$453M	−10%	FY2025
P/E	23.4	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.